Clinical trials: Melanoma Stage
Metastatic Kidney Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
This phase II trial studies how well image guided hypofractionated radiation therapy works with nelfinavir mesylate, pembrolizumab, nivolumab, and atezolizumab in treating patients with melanoma, lung cancer, or kidney cancer…
- Conditions
- Metastatic Kidney Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT03050060
- Testing
- Atezolizumab, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Washington
Metastasis From Malignant Melanoma of Skin (Diagnosis)
Irradiation of Melanoma in a Pulse
This is a single center phase I, first-in-human, dose escalation study of FLASH therapy in patients with metastases of melanoma.
- Trial name
- IMPulse (NCT04986696)
- Testing
- FLASH therapy
- Where
- Switzerland
- Volunteers
- 46 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Precancerous Condition, Stage 0 Melanoma
Lovastatin in Treating Patients At High Risk of Melanoma
The use of lovastatin may slow disease progression in patients at high risk of melanoma. It is not yet known whether lovastatin is more effective than a placebo in treating patients at high risk of melanoma.
- Conditions
- Precancerous Condition, Stage 0 Melanoma, Stage I Melanoma, Stage II Melanoma
- Trial name
- NCT00462280
- Testing
- lovastatin, biopsy, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma
A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases
This study will evaluate the efficacy and safety of cobimetinib plus atezolizumab in participants with BRAFV600 wild-type melanoma with central nervous system (CNS) metastases and of cobimetinib plus atezolizumab and vemurafenib…
- Trial name
- NCT03625141
- Testing
- Cobimetinib, Atezolizumab, Vemurafenib
- Where
- 22 sites in Brazil, France and 6 more
- Volunteers
- 80 people
- Sponsor
- Hoffmann-La Roche
Brain and Central Nervous System Tumors, Melanoma (Skin)
Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer
- Trial name
- NCT00002754
- Testing
- monoclonal antibody Me1-14 F(ab')2
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Duke University
Melanoma, Acral Melanoma
A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III Resectable Acral Melanoma
This is a prospective, multicenter, open-label, 1:1 randomized phase II trial enrolling 76 patients with AJCC stage III surgically resectable acral melanoma.
- Trial name
- NCT07854522
- Testing
- Iparomlimab and Tuvonralimab Injection (QL1706), OH2 Injection(Recombinant Human GM-CSF Oncolytic Type II Herpes Simplex Virus)
- Volunteers
- 76 people
- Sponsor
- Peking University Cancer Hospital & Institute
Metastatic Uveal Melanoma
Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)
Because we suspect that the benefit of anti-PD-1 in metastatic UM patients could vary according to previous exposure to Tebentafusp (better efficacy of anti-PD-1 after Tebentafusp), the combination of pembrolizumab and lenvatinib…
- Trial name
- PLUME (NCT05282901)
- Testing
- Pembrolizumab 25 MG/1 ML Intravenous Solution
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Institut Curie
Melanoma, Complication
Early Complications After Axillary and Inguinal Lymph Node Dissection in Stage III Melanoma Patients
This prospective randomized non-inferiority study is designed to compare the rate and severity of complications after axillary and inguinal lymph node dissection in stage III melanoma patients in a study group where the drain is…
- Trial name
- NCT04680182
- Testing
- Suction drain
- Where
- Norway
- Volunteers
- 104 people
- Sponsor
- Oslo University Hospital
Cancer
SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
This was a multi-center, open-label, Phase 1, first-in-human (FIH), dose-escalation, and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of SRK-181…
- Trial name
- NCT04291079
- Testing
- SRK-181, anti-PD-(L)1 antibody therapy
- Where
- 22 sites in United States, South Korea
- Volunteers
- 112 people
- Sponsor
- Scholar Rock, Inc.
Acral Lentiginous Malignant Melanoma, Ciliary Body and Choroid Melanoma, Medium/Large Size
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
This phase II trial is studying how well AZD2171 works in treating patients with recurrent or stage IV melanoma. AZD2171 may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes…
- Conditions
- Acral Lentiginous Malignant Melanoma, Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma
- Trial name
- NCT00243061
- Testing
- cediranib maleate
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Uveal Melanoma
Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma
After the local treatment of the primary tumor (protonbeam-therapy, enucleation, external radiotherapy) patients with high risk of metastasis are randomized between: Adjuvant chemotherapy with Fotemustin.
- Trial name
- FOTEADJ (NCT02843386)
- Testing
- Adjuvant chemotherapy by Fotemustin, Intensive surveillance
- Where
- 6 sites in France, Switzerland
- Volunteers
- 302 people
- Sponsor
- Institut Curie
Melanoma
Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).
This was a two-arm, randomized, double-blind Phase III study of dabrafenib in combination with trametinib versus 2 placebos in the adjuvant treatment of melanoma after surgical resection.
- Trial name
- COMBI-AD (NCT01682083)
- Testing
- Dabrafenib, Trametinib
- Where
- 168 sites in United States, Argentina and 23 more
- Volunteers
- 870 people
- Sponsor
- Novartis Pharmaceuticals
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Stage IIA Skin Melanoma, Stage IIB Skin Melanoma
MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery
This randomized pilot clinical trial studies melanoma antigen recognized by T-cells 1 (MART-1) antigen with or without toll-like receptor 4 (TLR4) agonist glucopyranosyl lipid A-stable oil-in-water emulsion (GLA-SE) in treating…
- Conditions
- Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma, Stage IIIA Skin Melanoma
- Trial name
- NCT02320305
- Testing
- MART-1 Antigen, TLR4 Agonist GLA-SE, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Mayo Clinic
Melanoma, Urothelial Carcinoma
Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma
This study will assess the safety, tolerability and efficacy of every-2-week dosing of QLF31907 injection in patients with advanced melanoma and urothelial carcinoma.
- Trial name
- NCT05823246
- Testing
- QLF31907
- Where
- 6 sites in China
- Volunteers
- 66 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Melanoma
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)
This study will evaluate the efficacy, safety, and pharmacokinetics of treatment combinations in cancer immunotherapy (CIT)-naive participants with resectable Stage III melanoma (Cohort 1) and in participants with Stage IV…
- Trial name
- NCT05116202
- Testing
- Nivolumab, Ipilimumab, RO7247669 2100 mg
- Where
- 14 sites in United States, Australia and 3 more
- Volunteers
- 110 people
- Sponsor
- Hoffmann-La Roche
the Efficacy and Safety of PD-1 Inhibitors With or Without Radiotherapy in Patients With Advanced Melanoma
PD-1 Inhibitors With or Without Radiation in Advanced Melanoma
This trial was a single-center, prospective, randomized controlled phase II trial. The objective was to evaluate the efficacy and safety of PD-1 inhibitors with or without radiotherapy in patients with advanced melanoma.
- Trial name
- NCT05498805
- Testing
- Radiation
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Fudan University
Carcinoma, Renal Cell, Kidney Diseases
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining varlilumab and atezolizumab.
- Conditions
- Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urogenital Neoplasms
- Trial name
- NCT02543645
- Testing
- Combination of Varlilumab and Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Celldex Therapeutics
Melanoma
Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab
The main goal of this research study is to determine how nivolumab and nivolumab/Vidutolimod (CMP-001) combination affect the likelihood of destroying melanoma involving lymph node and/or in-transit/satellite areas.
- Trial name
- NCT04401995
- Testing
- Vidutolimod (CMP-001), Nivolumab, [18F]F-AraG PET/CT
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Diwakar Davar
Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment…
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT03621982
- Testing
- ADCT-301, Pembrolizumab
- Where
- 9 sites in United States, Belgium and 1 more
- Volunteers
- 78 people
- Sponsor
- ADC Therapeutics S.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.